Skip to main content

Drug Interactions between finasteride and tacrolimus

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

finasteride tacrolimus

Applies to: finasteride and tacrolimus

MONITOR: Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity. Although clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of the drugs should be considered.

MANAGEMENT: Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.

References (2)
  1. (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
  2. (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories

Drug and food/lifestyle interactions

Major

tacrolimus food/lifestyle

Applies to: tacrolimus

GENERALLY AVOID: Grapefruit and/or grapefruit juice may increase the plasma concentrations of tacrolimus. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. Although clinical data are lacking, this interaction may result in increased risk of serious adverse reactions such as nephro- and neurotoxicity, as well as other adverse effects associated with tacrolimus such as malignancies, infections, diabetes, hyperkalemia, hypertension, and QT prolongation.

GENERALLY AVOID: Alcohol may modify the rate of tacrolimus release from extended release formulations, thereby potentially increasing the risk of serious adverse reactions.

ADJUST DOSING INTERVAL: Coadministration with food decreases the rate and extent of tacrolimus absorption. This effect is greatest after a high-fat meal.

MANAGEMENT: Patients should avoid consumption of food or drink containing grapefruit during treatment with tacrolimus. Concomitant use of tacrolimus, especially extended release formulations, with alcohol should also be avoided. Tacrolimus extended release formulations should be administered on an empty stomach, at least 1 hour before or 2 hours after a meal, and tacrolimus immediate release formulations should be taken consistently every day with or without food.

References (18)
  1. (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
  2. Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
  3. (2022) "Product Information. Adoport (tacrolimus)." Sandoz Ltd
  4. (2024) "Product Information. TACrolimus (Sandoz) (TACrolimus)." Sandoz Pty Ltd
  5. (2023) "Product Information. Prograf (tacrolimus)." Astellas Pharma US, Inc
  6. (2023) "Product Information. Astagraf XL (tacrolimus)." Astellas Pharma US, Inc
  7. (2025) "Product Information. Envarsus XR (tacrolimus)." Veloxis Pharmaceuticals
  8. (2024) "Product Information. Prograf (tacrolimus)." Astellas Pharma Canada Inc
  9. (2024) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Canada Inc
  10. (2024) "Product Information. Envarsus PA (tacrolimus)." Endo Operations LTD
  11. (2024) "Product Information. Dailiport (tacrolimus)." Sandoz Ltd
  12. (2025) "Product Information. Prograf (tacrolimus)." Astellas Pharma Ltd
  13. (2025) "Product Information. Envarsus (tacrolimus)." Chiesi Ltd
  14. (2025) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Ltd
  15. (2025) "Product Information. Modigraf (tacrolimus)." Astellas Pharma Ltd
  16. (2024) "Product Information. Advagraf XL (TACrolimus)." Astellas Pharma Australia Pty Ltd
  17. (2024) "Product Information. proGRAF (TACrolimus)." Astellas Pharma Australia Pty Ltd
  18. (2024) "Product Information. TACrolimus XR (Sandoz) (TACrolimus)." Sandoz Pty Ltd

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.